

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Haijun Sun	10/16/2009
Ling Liu	10/22/2009
RECEIVING PARTY DATA	
Name:	ImClone LLC
Street Address:	180 Varick Street
City:	New York
State/Country:	NEW YORK
Postal Code:	10014
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12579825
CORRESPONDENCE DATA	
Fax Number:	(317)276-3861
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	patents@lilly.com
Correspondent Name:	Eli Lilly and Company
Address Line 1:	P. O. Box 6288
Address Line 2:	Patent Division
Address Line 4:	Indianapolis, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X-18531
NAME OF SUBMITTER:	Linda M. Durbin
Total Attachments: 2 source=X18531Assignment#page1.tif source=X18531Assignment#page2.tif	

CH \$40.00 12579825

500999728

PATENT
REEL: 023433 FRAME: 0898

ASSIGNMENT**WHEREAS,**

Haijun SUN, 28 West 11th Street, Apt. 4A, New York, New York 10011; Citizenship: United States of America, and Ling LIU, 3393 Kilkenny Circle, Carmel, Indiana 46032, Citizenship: United States of America

are inventors of an invention that is the subject of a patent application ("Application") which is entitled FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR-3) INHIBITORS AND METHODS OF TREATMENT, containing 37 pages and 0 sheets of drawings, for filing:

- ☒ in the United States Patent and Trademark Office
- ☐ in the United Kingdom Patent Office
- ☐ in the European Patent Office
- ☐ in the Spanish Patent Office as a European Application
- ☐ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office

And accorded the following serial number and filing date: 12/579825, October 15, 2009.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number and filing date for the application when it is known.

WHEREAS IMCLONE LLC, a Delaware limited liability corporation having its principal place of business at 180 Varick Street, 6th Floor, New York, NY 10014, a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation with a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to ImClone LLC, its successors and assigns (collectively "ImClone") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by ImClone for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to ImClone not been made.


For myself and for my heirs, successors and legal representatives, I covenant that no

assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.


For myself and for my heirs, successors and legal representatives, I further covenant and agree with ImClone that upon request I and they will, without further consideration than that now paid, but at the expense of ImClone: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to ImClone any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for ImClone, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to ImClone or its nominees, in the United States and in all other countries where ImClone may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for ImClone and to vest and confirm in ImClone or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

10-16, 2009
Date


Haijun SUN

10-22, 2009
Date


Ling LIU

PATENT

RECORDED: 10/28/2009

REEL: 023433 FRAME: 0900